Kenji Takemoto

Kenji Takemoto

Auto-generated profile, based on publicly available information

Kenji Takemoto

Department of Pharmacology, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SNSyo Nakajima
Syo Nakajima
Koichi WatashiKoichi Watashi
Koichi Watashi
SKShinji Kamisuki
Shinji Kamisuki
STSenko Tsukuda
Senko Tsukuda
KTKenji Takemoto
Kenji Takemoto
TWTakaji Wakita
Takaji Wakita

14 September 2014 in Current Pathobiology Reports
Verified
Journal Article
Open access
PDF file
KIKeiko Iwaisako
Keiko Iwaisako
Kojiro TauraKojiro Taura
Kojiro Taura
YKYukinori Koyama
Yukinori Koyama
KTKenji Takemoto
Kenji Takemoto
MAMasataka Asagiri
Masataka Asagiri
Liver cirrhosis, a late stage of hepatic fibrosis, is an increasing cause of morbidity and mortality worldwide. Hepatic fibrosis is mainly caused by alcoholic or non-alcoholic steatohepatitis, chronic viral hepatitis, or autoimmune and biliary diseases. Myofibroblasts, which are absent from the normal liver, are differentiated from heterogeneous cell populations in response to a liver injury of any etiology and produce the extracellular matrix. Hepatic stellate cells are considered the main source of myofibroblasts. However, the origin of hepatic myofibroblasts remains unresolved, and despite considerable research, only a limited success has been achieved by existing anti-fibrotic therapies. The question remains whether these limitations are caused by lack of attention to the critical targets, the myofibroblasts derived from cells of other mesenchymal origins. Therefore, identifying the origin of myofibroblasts may provide insight into the mechanisms underlying liver fibrosis, and may lead to the development of more effective therapies. This review will examine our current strategies for detecting hepatic myofibroblasts of different origins.

1 February 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YMYoshiyuki Mizushina
Yoshiyuki Mizushina
HSHiroe Suzuki-Fukudome
Hiroe Suzuki-Fukudome
TTToshifumi Takeuchi
Toshifumi Takeuchi
KTKenji Takemoto
Kenji Takemoto
IKIsoko Kuriyama
Isoko Kuriyama
FSFumio Sugawara
Fumio Sugawara

2 August 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
AKAndaleb Kholmukhamedov
Andaleb Kholmukhamedov
LLLi Li
Li Li
CLChristopher C. Lindsey
Christopher C. Lindsey
JHJiangting Hu
Jiangting Hu
ANAnna-Liisa Nieminen
Anna-Liisa Nieminen
JLJohn J. Lemasters
John J. Lemasters
Mitochondrial chelatable iron contributes to the severity of several injury processes, including ischemia/reperfusion, oxidative stress, and drug toxicity. However, methods to measure this species in living cells are lacking. To measure mitochondrial chelatable iron in living cells, here we synthesized a new fluorescent indicator, mitoferrofluor (MFF). We designed cationic MFF to accumulate electrophoretically in polarized mitochondria, where a reactive group then forms covalent adducts with mitochondrial proteins to retain MFF even after subsequent depolarization. We also show in cell-free medium that Fe2+ (and Cu2+), but not Fe3+, Ca2+, or other biologically relevant divalent cations, strongly quenched MFF fluorescence. Using confocal microscopy, we demonstrate in hepatocytes that red MFF fluorescence colocalized with the green fluorescence of the mitochondrial membrane potential (ΔΨm) indicator, rhodamine 123 (Rh123), indicating selective accumulation into the mitochondria. Unlike Rh123, mitochondria retained MFF after ΔΨm collapse. Furthermore, intracellular delivery of iron with membrane-permeant Fe3+/8-hydroxyquinoline (FeHQ) quenched MFF fluorescence by ∼80% in hepatocytes and other cell lines, which was substantially restored by the membrane-permeant transition metal chelator pyridoxal isonicotinoyl hydrazone. We also show FeHQ quenched the fluorescence of cytosolically coloaded calcein, another Fe2+ indicator, confirming that Fe3+ in FeHQ undergoes intracellular reduction to Fe2+. Finally, MFF fluorescence did not change after addition of the calcium mobilizer thapsigargin, which shows MFF is insensitive to physiologically relevant increases of mitochondrial Ca2+. In conclusion, the new sensor reagent MFF fluorescence is an indicator of mitochondrial chelatable Fe2+ in normal hepatocytes with polarized mitochondria as well as in cells undergoing loss of ΔΨm.

1 January 2008 in World Journal of Gastroenterology
Verified
Journal Article
Open access
THTomohide Hori
Tomohide Hori
TWTakashi Wagata
Takashi Wagata
KTKenji Takemoto
Kenji Takemoto
TSTakanobu Shigeta
Takanobu Shigeta
HTHaruko Takuwa
Haruko Takuwa
NYNaoki Yokoo
Naoki Yokoo
A 71-year-old Japanese man with acute cholecystitis and an incarcerated gallbladder (GB) stone was admitted. Plain ultrasonography (US) incidentally detected a mass-like lesion in the fundus. Doppler US revealed that this elevated lesion had no blood flow. Computed tomography showed a relatively low-density mass, measuring 5 cm x 4 cm in diameter, with no positive enhancement. Magnetic resonance imaging showed a mass in the fundus with a slightly low intensity on T1-weighted images and a slightly high intensity on T2-weighted images. We were agonized in making the qualitative diagnosis of mass-like lesions of the fundus, such as a benign tumor, cancer, or debris. We performed laparoscopic cholecystectomy, because the incarcerated GB stone clearly caused acute cholecystitis. Intra-operative cholangiography clearly revealed pancreaticobiliary maljunction. Amylase levels in the common bile duct and gallbladder were quite high. The elevated lesion in the fundus clearly showed severe necrosis. Although this necrotic nodule included non-viable adenocarcinoma cells, viable cancer cell nests were located in the muscularis propria and subcutaneous layer. Histopathological examination confirmed a solid adenocarcinoma. Thus, we diagnosed it as a gallbladder cancer, based on histopathological analysis of the resected specimen. We therefore undertook radical surgery, including wedge resection of the liver, radical dissection of regional lymph nodes, and resection of the extrahepatic bile duct. Histopathological findings revealed no cancer, hyperplasia or dysplasia in the additionally resected specimens. The patient was finally staged as T2, N0, H0, P0, M(-), stage II. We present the first case of spontaneous necrosis of solid gallbladder adenocarcinoma, with a review of previous studies.

26 July 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MSMatthew Savoca
Matthew Savoca
KTKenji Takemoto
Kenji Takemoto
JHJiangting Hu
Jiangting Hu
LLLi Li
Li Li
BKB. Jacob Kendrick
B. Jacob Kendrick
JLJohn J. Lemasters
John J. Lemasters